Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre Goy

Showing results (131-140 of 164) with videos related to

Pageof 17
Sort By:
Leukemia|September 28, 2019
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Haematologica|February 9, 2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisAnthony R Mato, Chadhi Nabhan, Meghan C Thompson, et al.
American Journal of Hematology|January 30, 2026
CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeSilvia Escribano-Serrat, Ofrat Beyar-Katz, Roni Shouval, et al.
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Blood Cancer Journal|February 2, 2022
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithmsMaher Albitar, Hong Zhang, Andre Goy, et al.
Blood Advances|December 5, 2023
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T ConsortiumMichael D Jain, Miriam T Jacobs, Feng Gao, et al.
Blood|November 6, 2020
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapyJay Y Spiegel, Saurabh Dahiya, Michael D Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host DiseaseJennifer N Brudno, Robert P T Somerville, Victoria Shi, et al.
Blood|February 22, 2013
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantationDaniel H Fowler, Miriam E Mossoba, Seth M Steinberg, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2022
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T ConsortiumMiriam T Jacobs, Michael D Jain, Feng Gao, et al.
Pageof 17

Showing results (131-140 of 164) with videos related to

Sort By:
Pageof 17
Leukemia|September 28, 2019
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Haematologica|February 9, 2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisAnthony R Mato, Chadhi Nabhan, Meghan C Thompson, et al.
American Journal of Hematology|January 30, 2026
CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeSilvia Escribano-Serrat, Ofrat Beyar-Katz, Roni Shouval, et al.
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Blood Cancer Journal|February 2, 2022
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithmsMaher Albitar, Hong Zhang, Andre Goy, et al.
Blood Advances|December 5, 2023
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T ConsortiumMichael D Jain, Miriam T Jacobs, Feng Gao, et al.
Blood|November 6, 2020
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapyJay Y Spiegel, Saurabh Dahiya, Michael D Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host DiseaseJennifer N Brudno, Robert P T Somerville, Victoria Shi, et al.
Blood|February 22, 2013
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantationDaniel H Fowler, Miriam E Mossoba, Seth M Steinberg, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2022
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T ConsortiumMiriam T Jacobs, Michael D Jain, Feng Gao, et al.
Pageof 17